Other clinical endpoints showing benefit
Other clinical endpoints demonstrating a benefit for interferon-beta1b in secondary progressive MS include:
- time to being wheelchair bound
- number of steroid courses required
- number of admissions to hospital
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.